[서울=뉴스프리존]Reporter Lee Dong-geun = Daewoong Pharmaceutical released the clinical results of Phase 2a on the treatment effect of’Hoy Star Tablet’ on the 23rd.
According to Daewoong Pharmaceutical, this clinical trial was conducted in a placebo-controlled, randomized, and double-blind method for a total of 89 mild or asymptomatic confirmed patients hospitalized for COVID-19 with the participation of Professor Myung-don Oh of Seoul National University and researchers from 13 institutions, who are the lead researcher Excluding dropouts, a total of 81 patients (41 patients in the Hoystar group, average age 55 years old / 40 patients in the placebo group, average age 43 years) were compared to analyze clinical efficacy and safety.
Daewoong Pharmaceutical said, “The time taken until the virus negative prevalence, the main evaluation variable, was not statistically significant, but the rate at which the virus was removed tended to be faster in the Hoystar group than in the placebo group.” The company explained that the result is remarkable considering that the mechanism of action of Hoystar is not a drug that directly kills the virus, but a mechanism that blocks the entry of the virus into the cell (TMPRSS2 inhibitor).
As a result of the analysis of the time it took for the patient’s clinical symptoms to improve, the sequence scale (the ranking scale for clinical signs in Corona 19) and the news score (a scale that quantified the severity of the patient), recovery tended to be faster in the Hoystar group. . As the result of improvement of the symptom scale is of great clinical significance, detailed analysis will be conducted.
The current results are top-line results, and since all figures have not been analyzed so far, the final results will be officially published in the journal through further analysis and in-depth consideration with clinical participants and experts in infectious medicine.
Seung-ho Jeon, president of Daewoong Pharmaceutical, said, “As a result of this phase 2a test, the belief that self-treatment can be made possible by taking Hoystar tablets was confirmed in this clinical trial following the retrospective analysis results.” He said, “Because of the situation, we will quickly draw the same results in large-scale patients and secure the results of phase 3 clinical trials within the first half of 2021 so that Hoystar can establish itself as a global COVID-19 treatment.”
Copyright © News Free Zone Unauthorized reproduction and redistribution prohibited